Clinical trials: Polymyalgia Rheumatic (PMR)
Polymyalgia Rheumatica
Validation of the PMR Activity Score and Evolution of Patient-reported Outcomes in Patients With Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a systemic inflammatory disease that affects elderly people. It is characterized by pain and morning stiffness in the shoulders, pelvic girdles and neck.
- Trial name
- NCT05542316
- Where
- Belgium
- Volunteers
- 133 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Polymyalgia Rheumatica
A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR
The study compares the efficacy and safety of modified release prednisone versus immediate release prednisone in patients suffering from polymyalgia rheumatica.
- Trial name
- NCT01821040
- Testing
- Lodotra®, Prednisone IR (immediate release)
- Where
- United Kingdom
- Volunteers
- 62 people
- Sponsor
- Mundipharma Research Limited
Giant Cell Arteritis, Polymyalgia Rheumatic (PMR)
Giant Cell Arteritis - Ways to Precision Medicine
Long-term follow-up of aortal adverse events, as well as glucocortioid-associated adverse events in patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).
- Trial name
- NCT07084480
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Wuerzburg University Hospital
Polymyalgia Rheumatica, Rheumatoid Arthritis
Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica
The aim of this study is to evaluate a simple and rapid method in order to better define and treat Polymyalgia Rheumatica by measuring levels of muscle achiness and pain with a blood pressure cuff.
- Conditions
- Polymyalgia Rheumatica, Rheumatoid Arthritis, Rheumatic Disease
- Trial name
- NCT00847236
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Lahey Clinic
Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA)
Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis
This prospective study is to explore different predictive factors for response to steroid treatment in patients with PMR and/or GCA.
- Trial name
- NCT05479448
- Testing
- Data collection for cellular analyses (Immune subset composition, GCR expression, in vitro steroid responsiveness), Data collection for exploratory analyses of endogenous steroid hormones, Data collection for correlation between clinical defined and lab defined GC responsivness
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Hospital, Basel, Switzerland
Polymyalgia Rheumatica
Delayed Release Prednisone in PMR
A four-week, randomized, controlled, open-label trial of DR prednisone in which patients receive in period 1 one of three-night time doses of treatment (4mg, 7mg or 10mg) for two weeks followed in period 2 by treatment with 15mg…
- Trial name
- NCT02702778
- Testing
- Delayed-Release (DR) Prednisone, Immediate Release (IR) Prednisone
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Dinora, Inc.
Polymyalgia Rheumatica
Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS
Polymyalgia rheumatic (PMR) is a frequent inflammatory disease. It affects the elderly, with peak incidences at the age of 70 to 80 years; an age >50 years or older, is considered a criterion for the diagnosis.
- Trial name
- ALORS (NCT03632187)
- Testing
- Abatacept
- Where
- 5 sites in France
- Volunteers
- 34 people
- Sponsor
- University Hospital, Brest
Polymyalgia Rheumatica (PMR)
DNA Methylation in PMR
Polymyalgia Rheumatica (PMR) is treated with corticosteroids; however, long-term treatment is not feasible due to side effects. Withdrawal of corticosteroids causes a subset of patients to relapse, and there is no current way to…
- Trial name
- NCT07748195
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Polymyalgia Rheumatica
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
- Trial name
- REPLENISH-EXT (NCT06331312)
- Testing
- Secukinumab
- Where
- 85 sites in United States, Argentina and 20 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Polymyalgia Rheumatica
Tocilizumab Effect iN pOlymyalgia Rheumatica
Phase 1: Patients are treated with infusions of Tocilizumab (TCZ) for 3 months. Clinical evaluation is performed using PMR-AS. The PMR-AS is computed by summing the 5 variables after multiplying by 0.1 for weighting purposes…
- Trial name
- TENOR (NCT01713842)
- Testing
- TCZ
- Where
- 3 sites in France
- Volunteers
- 21 people
- Sponsor
- University Hospital, Brest
Giant Cell Arteritis, Polymyalgia Rheumatica
Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)
A multi-centre observational study recruiting prospective and retrospective cohorts of patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).
- Trial name
- NCT04102930
- Where
- 76 sites in United Kingdom
- Volunteers
- 4,500 people
- Sponsor
- University of Leeds
Polymyalgia Rheumatica
Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica
This will be efficacy and safety of Induction and Tapering Therapy with Tofacitinib and Glucocorticoid in patients with Polymyalgia Rheumatica (ITTG PMR): An open-label 52-week randomized controlled trial
- Trial name
- ITTGPMR (NCT06172361)
- Testing
- Prednisone+Tofacitinib, Prednisone
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Zhejiang University
Polymyalgia Rheumatica
A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)
This will be an open label phase 1b trial to characterize the pharmacodynamics and PK of prednisolone and SPI-62 when co-administered to participants with PMR. Up to 24 participants could be recruited.
- Trial name
- NCT06281236
- Testing
- Prednisolone, SPI-62
- Where
- 5 sites in Germany
- Volunteers
- 1 people
- Sponsor
- Sparrow Pharmaceuticals
Polymyalgia Rheumatica (PMR)
Using Personalized Rehabilitation to Reduce Disease and Increase Activity of Patients With Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a condition that causes joint pain and stiffness, making it hard for people to do everyday tasks.
- Trial name
- NCT07749547
- Testing
- Movement Pattern Training (MoveTrain), Usual Care
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Polymyalgia Rheumatica
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154
Polymyalgia rheumatica (PMR) is an inflammatory disease causing shoulder, hip, and neck pain and stiffness, in adults aged 50 years or older.
- Trial name
- AIM-PMR (NCT04972968)
- Testing
- ABBV-154, Glucocorticoid
- Where
- 117 sites in United States, Australia and 13 more
- Volunteers
- 181 people
- Sponsor
- AbbVie
Polymyalgia Rheumatica
A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)
The purpose of this study is to assess the efficacy of a tocilizumab-based regimen compared with placebo on top of rapidly tapered glucocorticoid treatment in a double- blind, controlled fashion, focussing on glucocorticoid-free…
- Trial name
- NCT03263715
- Testing
- Tocilizumab Prefilled Syringe [Actemra], Glucocorticoids
- Where
- 3 sites in Austria
- Volunteers
- 39 people
- Sponsor
- Medical University of Vienna
Polymyalgia Rheumatica (PMR)
Study of Tocilizumab to Treat Polymyalgia Rheumatica
This is a fifteen-month open label, Phase IIa clinical trial is being conducted to assess the tolerability, safety and efficacy of a medication called Tocilizumab (Actemra®) in patients with polymyalgia rheumatica (PMR).
- Trial name
- NCT01396317
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hospital for Special Surgery, New York
Giant Cell Arteritis, Polymyalgia Rheumatica
DANIsh VASculitis Database (DANIVAS)
The aim of this national pragmatic observational study is to investigate whether the use of new diagnostic imaging modalities facilitates disease stratification that can potentially predict treatment response, relapse risk and…
- Trial name
- DANIVAS (NCT05935709)
- Where
- 2 sites in Denmark
- Volunteers
- 3,000 people
- Sponsor
- Aarhus University Hospital
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.
Ankylosing spondylitis, radiographically negative axial spondyloarthritis, psoriatic arthritis, polymyalgia rheumatica, Takayasu arteritis, giant cell arteritis, non-ocular Behcet's disease, and enthesitis-related arthritis are…
- Conditions
- Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Nr-axSpA, Polymyalgia Rheumatica (PMR)
- Trial name
- V-MIRACLE (NCT06766552)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Systemic Vasculitis, Spondylarthropathies
Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
The purpose of HZ-REUMA study is explore vaccine response and protection against shingles (herpes zoster, HZ) after vaccination with two doses of Shingrix in immunosuppressed patients with inflammatory rheumatic diseases (IRD)…
- Conditions
- Systemic Vasculitis, Spondylarthropathies, Psoriatic Arthritis, Scleroderma
- Trial name
- HZ-REUMA (NCT06763783)
- Testing
- Shingrix, vaccination with 2 doses of Shingrix vaccine
- Where
- Sweden
- Volunteers
- 240 people
- Sponsor
- Region Skane